Shanks C A, Avram M J, Fragen R J, O'Hara D A
Department of Anesthesia, Northwestern University, Chicago, IL 60611.
Clin Pharmacol Ther. 1987 Oct;42(4):459-64. doi: 10.1038/clpt.1987.178.
Vecuronium was administered to two patient groups as a single intravenous dose, 60 micrograms/kg, combined with an infusion, 1 microgram/min/kg. Anesthesia was maintained for the first group with a halothane-nitrous oxide technique; the second group received fentanyl-barbiturate-tranquilizer-nitrous oxide. As the infusion ended, plasma vecuronium concentrations were 0.34 (+/- 0.10) microgram/ml for the halothane group and 0.32 (+/- 0.07) microgram/ml for the fentanyl group, associated with 93% (+/- 8) and 88% (+/- 10) twitch depression, respectively. Vecuronium plasma concentration-time data were combined with the simultaneous intensities of neuromuscular blockade to model the kinetic-dynamic values for each patient. For the halothane group the steady-state volume was 0.21 (+/- 0.04) L/kg, the clearance was 2.9 (+/- 0.1) ml/min/kg, and the elimination half-life was 100 (+/- 36) minutes; for the fentanyl group these were 0.20 (+/- 0.08) L/kg, 3.2 (+/- 0.1) ml/min/kg, and 84 (+/- 43) minutes, respectively. Plasma concentrations associated with 50% blockade averaged 0.2 microgram/ml for both groups. Neither the pharmacokinetics nor the pharmacodynamics of vecuronium in humans differed between these two patient groups.
维库溴铵以60微克/千克的单一静脉剂量给予两个患者组，并同时以1微克/分钟/千克的速度进行输注。第一组采用氟烷 - 氧化亚氮技术维持麻醉；第二组接受芬太尼 - 巴比妥酸盐 - 镇静剂 - 氧化亚氮麻醉。输注结束时，氟烷组的血浆维库溴铵浓度为0.34（±0.10）微克/毫升，芬太尼组为0.32（±0.07）微克/毫升，分别伴有93%（±8）和88%（±10）的颤搐抑制。将维库溴铵的血浆浓度 - 时间数据与同时的神经肌肉阻滞强度相结合，以模拟每个患者的动力学 - 动态值。氟烷组的稳态容积为0.21（±0.04）升/千克，清除率为2.9（±0.1）毫升/分钟/千克，消除半衰期为100（±36）分钟；芬太尼组分别为0.20（±0.08）升/千克、3.2（±0.1）毫升/分钟/千克和84（±43）分钟。两组引起50%阻滞的血浆浓度平均均为0.2微克/毫升。这两个患者组中维库溴铵在人体内的药代动力学和药效学均无差异。
